Choroidal melanoma is the most common primary intraocular ... to identify the high-risk patients who will require treatment with targeted adjuvant agents before metastasis occurs.

The summer of 2023 saw the approval of a new treatment option for certain ... in early-stage choroidal melanoma. Bel-sar is from a novel class of virus-like drug conjugate therapies that Boston ...

While melanoma is much less common than other types of skin cancer, it is the most serious because it is more likely to ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Morning Pointe Senior Living announces Fred Hutagaol has been selected as the recipient of the Morning Pointe Scholars Endowment scholarship at Southern Adventist University. “The Morning ... more ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

Choroidal neovascularization (CNV ... In the last 20 years, there have been rapid advances in the treatment options for myopic CNV. The aim of this article is to give an overview of several ...

The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in 184 patients with advanced melanoma who have relapsed after or not responded to treatment ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

After hours: February 12 at 4:02:16 PM EST Loading Chart for AURA ...